Treatment strategy for patients with platinum-sensitive ovarian cancer using PARP inhibitors

Abstract

Abstract After a brief summary of the current status of poly-ADP ribose polymerase (PARP) inhibitors for ovarian cancer, I summarize the current status and future perspectives of treatment strategy with PARP inhibitors, in the platinum-sensitive setting. Topics include; 1) gene alterations other than BRCA, 2) homologous recombination deficiency (HRD), and 3) combinations. Discussions of gene alterations other than BRCA cover the results of multiple gene panels testing homologous recombination repair deficiency genes and cancer susceptibility genes, and influences of these alterations on efficacy of PARP inhibitors and cancer susceptibility. Discussions of HRD focus on the results of phase 3 trials using HRD assay, the definition of HRD assays, and the other latest assays. I just shortly refute to combinations because this topic will be covered by other presenters. It includes early phase trial results and ongoing trials combining PARP inhibitors with immune checkpoint inhibitors, anti-angiogenic agents, and triplets.